Abstract
Inborn errors of metabolism have been considered as an infrequent cause of epilepsy. Improvement in diagnostics has improved the detection of a metabolic basis of recurrent seizures in neonates and children. The term 'metabolic epilepsy' is used to suggest inherited metabolic disorders with predominant epileptic manifestations as well as those where epilepsy is part of the overall neurological phenotype. Several of these disorders are treatable, and the physician should bear in mind the classical ages of presentation. As there are no specific clinical or electrographic features suggestive of metabolic epilepsies, an early suspicion is based on clinical and laboratory clues. Fortunately, with the advancement of gene sequencing technology, a diagnosis of these rare conditions is more straightforward and may not require invasive procedures such as biopsies, multiple metabolic stress-induced testing for abnormalities, and cerebrospinal fluid analysis. A gene panel may suffice in most cases and can be done from a blood sample. In many countries, many treatable metabolic disorders are now part of the neonatal screen. Early diagnosis and treatment of these disorders can result in the prevention of a full-scale metabolic crisis and improvement of neurological outcomes. Long-term neurological outcomes are variable and additional therapies may be required.
Similar content being viewed by others
References
Campistol J. Epilepsy in inborn errors of metabolism with therapeutic options. Semin Pediatr Neurol. 2016;23:321–31.
Tumiene B, Peterlin B, Maver A, Utkus A. Contemporary scope of inborn errors of metabolism involving epilepsy or seizures. Metab Brain Dis. 2018;33:1781–6.
van Karnebeek CDM, Sayson B, Lee JJY, et al. Metabolic evaluation of epilepsy: a diagnostic algorithm with focus on treatable conditions. Front Neurol. 2018;9:1016.
Lin Lin Lee V, KarMeng Choo B, Chung YS, P Kundap U, Kumari Y, Shaikh MF. Treatment, therapy and management of metabolic epilepsy: a systematic review. Int J MolSci. 2018;19:871.
Prasad AN, Hoffmann GF. Early onset epilepsy and inherited metabolic disorders: diagnosis and management. Can J Neurol Sci. 2010;37:350–8.
Pascual JM, Campistol J, Gil-Nagel A. Epilepsy in inherited metabolic disorders. Neurologist. 2008;14:S2-14.
Sharma S, Prasad AN. Inborn errors of metabolism and epilepsy: current understanding, diagnosis, and treatment approaches. Int J Mol Sci. 2017;18:1384.
Wolf NI, Garcia-Cazorla A, Hoffmann GF. Epilepsy and inborn errors of metabolism in children. J Inherit Metab Dis. 2009;32:609.
Rahman S, Footitt EJ, Varadkar S, Clayton PT. Inborn errors of metabolism causing epilepsy. Dev Med Child Neurol. 2013;55:23–36.
van Karnebeek CD, Jaggumantri S. Current treatment and management of pyridoxine-dependent epilepsy. Curr Treat Options Neurol. 2015;17:335.
van Karnebeek CD, Stockler-Ipsiroglu S, Jaggumantri S, et al. Lysine-restricted diet as adjunct therapy for pyridoxine-dependent epilepsy: the PDE Consortium Consensus Recommendations. JIMD Rep. 2014;15:1–11.
Mills PB, Camuzeaux SS, Footitt EJ, et al. Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain. 2014;137:1350–60.
Mills PB, Surtees RA, Champion MP, et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5’-phosphate oxidase. Hum Mol Genet. 2005;14:1077–86.
Tremino L, Forcada-Nadal A, Rubio V. Insight into vitamin B6 -dependent epilepsy due to PLPBP (previously PROSC) missense mutations. Hum Mutat. 2018;39:1002–13.
Gallagher RC, Van Hove JL, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol. 2009;65:550–6.
Pope S, Artuch R, Heales S, Rahman S. Cerebral folate deficiency: analytical tests and differential diagnosis. J Inherit Metab Dis. 2019;42:655–72.
Wolf B. Biotinidase deficiency: “If you have to have an inherited metabolic disease, this is the one to have.” Genet Med. 2012;14:565–75.
Dhawan SR, Sharawat IK, Saini AG, Suthar R, Attri SV. Diaper rash in an infant with Seizures. J Pediatr. 2019;206:296.
Kasinathan A, Suthar R, Vyas S, Saini AG, Sankhyan N, Attri S. Subacute myelopathy: think beyond neuromyelitis optica spectrum disorder. Ann Indian Acad Neurol. 2019;22:541–2.
Applegarth DA, Toone JR. Glycine encephalopathy (nonketotic hyperglycinaemia): review and update. J Inherit Metab Dis. 2004;27:417–22.
Van Hove JL, Vande Kerckhove K, Hennermann JB, et al. Benzoate treatment and the glycine index in nonketotic hyperglycinaemia. J Inherit Metab Dis. 2005;28:651–63.
Gramer G, Wolf NI, Vater D, et al. Glucose transporter-1 (GLUT1) deficiency syndrome: diagnosis and treatment in late childhood. Neuropediatrics. 2012;43:168–71.
Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev. 2009;31:545–52.
Sharer JD, Bodamer O, Longo N, Tortorelli S, Wamelink MM, Young S. Laboratory diagnosis of creatine deficiency syndromes: a technical standard and guideline of the American College of Medical Genetics and Genomics. Genet Med. 2017;19:256–63.
Clark JF, Cecil KM. Diagnostic methods and recommendations for the cerebral creatine deficiency syndromes. Pediatr Res. 2015;77:398–405.
van der Crabben SN, Verhoeven-Duif NM, Brilstra EH, et al. An update on serine deficiency disorders. J Inherit Metab Dis. 2013;36:613–9.
Dhawan SR, Saini AG, Vyas S, Attri SV. Teaching neuroimages: when MRI is a clue in episodic ataxia. Neurology. 2019;93:e2074–5.
Cosnahan AS, Campbell CT. Inborn errors of metabolism in pediatric epilepsy. J Pediatr Pharmacol Ther. 2019;24:398–405.
Author information
Authors and Affiliations
Contributions
CR: Drafting the manuscript; AGS: Drafting and revising the manuscript. AGS will act as guarantor for this paper.
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Reddy, C., Saini, A.G. Metabolic Epilepsy. Indian J Pediatr 88, 1025–1032 (2021). https://doi.org/10.1007/s12098-020-03510-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-020-03510-w